Clinical trial · Interventional
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cadonilizumab combined with neoadjuvant radiochemotherapy | Combination Product | — | UNRESOLVED |
| neoadjuvant radiochemotherapy | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1: cadonilizumab combined with neoadjuvant radiochemotherapy
- description
- Subjects randomized in Arm 1 will be treated with cadonilizumab plus neoadjuvant radiochemotherapy before surgery.
- interventionNames
- Combination Product: cadonilizumab combined with neoadjuvant radiochemotherapy
- type
- PLACEBO_COMPARATOR
- label
- Arm 2: neoadjuvant radiochemotherapy
- description
- Subjects randomized in Arm 2 will be treated with neoadjuvant radiochemotherapy before surgery.
- interventionNames
- Combination Product: neoadjuvant radiochemotherapy
Primary outcomes (1)
- measure
- pCR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed with esophageal squamous cell cancer; * staged with cT1N+M0/cT2-3N0-3M0; * experienced no cancer-related treatment; * ECOG 0-1; * Expected survival more than 6 months; * aimed at neoadjuvant therapy for surger; * have adquate organ function. Exclusion Criteria: * diagnosed with other types of cancer during last five years; * have a tendency to bleed; * accepted any type of cancer-related therapy.
References
Publications (0)
Data not yet available